Australian biotech market watch 01/06/09
Monday, 01 June, 2009
All Ordinaries are up across the board by 1.5% as further signs of recovery were being warmly welcomed by stock markets around the world. In line with the rise, health indices are up 1.1% after high volumes of trading compared to a fairly deflated week last week. CSL Limited (ASX:CSL) up 45c to $29.65 on the back of the US Government placing a $230 million dollar order to produce Novel A (H1N1) influenza vaccine antigen. Other risers include Probiotec (ASX:PBP), up 11c to $1.86 and Sonic Healthcare (ASX:SHL), which lifted 2.5% to $12.12. Flurotechnics bucked the trend, plummeting a dramatic 64.3% to 25c and CathRx (ASX:CXD) dropped 4c to 51c after releasing its quarterly investor update.
Babies of stressed mothers likely to get their teeth earlier
Maternal stress during pregnancy can speed up the timing of teeth eruption, which may be an early...
Customised immune cells used to fight brain cancer
Researchers have developed CAR-T cells — ie, genetically modified immune cells manufactured...
Elevated blood protein levels predict mortality
Proteins that play key roles in the development of diseases such as cancer and inflammation may...
